Integrated multi-omics reveals dysbiosis in hemodialysis patients: A multi-center study Authors: Xinyue Zhang, Dan Yu, Yupeng Cui, Yanqing Chi, Zhenyu Yan, Yang Song, Liping Hou, Jin Qin, Jingjing Zhang, Yuanyuan Wang, Wei Wei, Hailing Di, Hongtao Bi, Ze Xiang, Ze Xiang Published: 2026 ABSTRACT IntroductionThe gut microbiome-metabolome interplay in hemodialysis (HD) patients remains poorly characterized. Using multi-omics approaches, we compared HD patients with healthy controls (HC) to identify microbial signatures, metabolic perturbations, and their integrated correlations.MethodsThis case-control study included 192 participants (96 HD-HC pairs under identical dietary and living conditions). The gut microbiota composition was analyzed using 16S ribosomal RNA gene sequencing, and fecal metabolomes were analyzed using ultra-high-performance liquid chromatography and high-resolution mass spectrometry (UPLC-HRMS). A multi-omics analysis was conducted utilizing Spearman correlation analysis, Mantel test analysis, and differential functional pathway analysis.ResultsWe observed significant differences in gut microbiota composition between the HD and HC groups, such as Ruminococcus and Bifidobacterium. Comparative analysis revealed 497 significantly altered metabolites in the HD group versus HC, primarily associated with amino acid, vitamin, lipid, purine, and pyrimidine metabolisms. ROC analysis identified 4-pyridoxic acid, nudifloramide, imidazoleacetic acid, ascorbic acid, and tocopheronic acid as potential diagnostic biomarkers (AUC > 0.8, p < 0.01). Integrated multi-omics analysis revealed correlations between Ruminococcus and metabolites such as Docosapentoic acid (DPA), 13 − EPAHAAB (EPA), and tryptamine, with shared differential pathways in bile secretion, caffeine metabolism, gastric acid secretion, and vitamin B6 metabolism.ConclusionHemodialysis patients exhibited significant alterations in gut microbiota composition and metabolic profiles (amino acid, vitamin, and lipid metabolism) compared with healthy controls, with demonstrated microbiome-metabolome interactions and shared functional pathways. The potential diagnostic and therapeutic value of these differential features warrants further exploration and external validation. Introduction Chronic kidney disease (CKD) has emerged as a growing public health concern [1]. Globally, hemodialysis (HD) is the predominant modality, used by approximately 85% of dialysis patients, whereas peritoneal dialysis (PD) accounts for about 11%, with substantial variation across countries [2,3]. According to the latest data from the China National Renal Data System (CNRDS), HD constituted approximately 86.8% of the dialysis population in China, and the number of patients receiving maintenance hemodialysis reached 1,027,267 by the end of 2024 [4]. Moreover, the prevalence of malnutrition in HD patients is as high as 30.0% ~ 66.7% [5]. Therefore, it is crucial to find targets to improve nutritional and disease status in HD patients. The microbial ecology of the human gastrointestinal tract (GIT) is highly diverse. However, uremia causes gut dysbiosis-a disorder that alters the normal makeup and activity of the gut microbiota. Taxonomic and functional changes in the GIT microbiome have been linked to numerous illnesses, including inflammatory bowel disease (IBD) [6,7], malnutrition [8,9], cardiovascular events [10], higher mortality risk [11-12], and metabolic disorders [13]. Increased α-diversity, a measure of bacterial evenness and richness, is generally linked to better health outcomes [14]. Recent studies have reported that patients receiving hemodialysis exhibit alterations in gut microbial diversity; however, the direction of change remains inconsistent. Some studies have observed a dramatic decrease in gut microbial diversity in HD patients, which is strongly associated with malnutrition and inflammation [15,16], whereas others have reported increased richness or no significant differences in diversity indices [17,18]. These discrepancies may arise from differences in study populations, dietary habits, living environments, and insufficient control of confounding factors. Even after controlling for influencing variables including age, BMI, dietary habits, and living environment, it remains unclear whether consistent differences in gut microbiota exist between HD patients and healthy controls (HC). Metabolomics systematically captures dynamic changes in small-molecule metabolites. In the context of disease, it can uncover disrupted metabolic pathways and support the identification of therapeutic targets and early diagnostic biomarkers [19–21]. Although metabolomics has been used to identify indicators linked to the advancement of chronic kidney disease, most studies have focused on serum metabolomics [22,23]. Morgan E. Grams and colleagues discovered that several metabolites, including kynurenate, hippurate, and homocitrulline, are associated with the advancement of chronic kidney disease [24]. Shengyuan Luo et al. identified 58 serum metabolites with cross-sectional relationships to proteinuria; several of these metabolites were also connected to the advancement of chronic kidney disease (CKD) [25]. While metabolomics has emerged as a promising area of research in human diseases, our understanding of fecal metabolic activity in patients receiving hemodialysis remains limited, and the differences in metabolism and metabolic pathways between HD patients and healthy individuals are poorly characterized. Furthermore, in the context of CKD, coordinated multi-omics research is crucial to improving our comprehension of the complex interactions between host health and microbial diversity. Therefore, the primary objective of this study was to evaluate differences between HD patients and HC individuals in gut microbial diversity, fecal metabolite profiles, and associated metabolic pathways using a 1:1 matched case-control design. The secondary objective was to perform integrated multi-omics analysis to examine correlations among identified microbial species, metabolites, and functional pathways, thereby generating hypotheses for future mechanistic and translational studies. Materials and methods Study design and patient population This study was a multicenter prospective 1:1 matched case-control study. Hemodialysis (HD) patients were recruited from four dialysis centers in Hebei Province, China, including one provincial and three municipal hospitals. Participants were recruited through two approaches: (1) public posters in dialysis centers, and (2) face-to-face interviews by trained research staff. Data were prospectively collected between July 2023 and April 2024. This study was approved by the Ethics Committee of the Third Hospital of Hebei Medical University (Approval No. W2024-012-1). All participants provided written informed consent. All methods were performed in accordance with the relevant guidelines and regulations. No waiver of informed consent was granted, as all participants were competent and willing to sign the consent form. Matching strategy. Each HD patient was paired with a healthy control living in the same household and sharing the same diet and living environment. This household paired design is grounded in the principle that cohabitation substantially reduces individual variability in gut microbiota composition and enhances statistical power [26]. Similar designs have been successfully used in previous microbiome studies [27–28]. Age, sex, height, weight, and BMI were not used as matching criteria; they are reported in S1 Table only as descriptive characteristics of the two groups after matching. Inclusion criteria for HD patients. (1) age 18–80 years; (2) regular hemodialysis for > 3 months; (3) adequate dialysis adequacy (Kt/v > 1.2); Inclusion criteria for HC: (1) living and eating with the corresponding HD patient and providing written informed consent; (2) age within ± 2 years of the patient; (3) willingness to provide a fecal sample and comply with the study procedures. Exclusion criteria for both groups. (1) severe cardiopulmonary, hepatic, or renal diseases, malignancies, or gastrointestinal disorders; (2) autoimmune diseases or long-term immunosuppressant use; (3) peritonitis or other severe infections within the past month; (4) surgery within the past month; (5) fever, abdominal pain, or diarrhea within the past two weeks; (6) use of probiotics or prebiotic supplements; (7) use of antibiotics within 3 months prior to enrollment; Additional exclusion criteria for HC: (1) use of antibiotics or probiotics within 3 months prior to enrollment; (2) history of travel to a region geographically distinct from the dialysis patient cohort; (3) gastrointestinal disorders (e.g., diarrhea) preventing stool collection. Dietary intake survey and evaluation We conducted a 3-day, 24-hour dietary recall survey for participants through face-to-face interviews [29]. Average daily energy and nutrient intake were determined by using specialized nutrition software (Nutrition Clinic Management System, V1.27.2-N, Shanghai Weihu Computer Tec Co., Ltd). The case and control groups cohabited and shared identical dietary sources, with no significant differences in mean daily per capita nutrient intake (all p > 0.05, S2 Table), confirming that the household matching strategy successfully achieved comparable dietary intake between groups and effectively minimized diet as a confounding factor. Clinical data and laboratory measurements Anthropometric measurements and body composition evaluations were performed by trained professionals subsequent to the mid-week hemodialysis treatment. An automatic height and weight meter (InBody BSM370, Biospace, Korea) was used to measure our height and weight. Body mass index (BMI) was calculated as weight divided by the square of height in meters: BMI = weight (kg) / [height (m)]². During the on-site study, clinical data were gathered. Every participant had to take measurements while wearing light clothing and after a 12-hour fast. Following an 8-hour fast, blood was taken right before the midweek dialysis session. An automated biochemistry analyzer (BS-360S, Catalog No. 116-022-100; Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China) was used to perform blood biochemistry studies, such as albumin (ALB), prealbumin (PA), uric acid (UA), etc. MIS (Malnutrition-inflammation score) [30–31] and Neutrophil-lymphocyte Ratio (NLR) were used for the evaluation of the nutritional status and the inflammation status. Fecal sample collection Fecal samples were obtained at home using a disposable stool collection cup and transported to the hospital laboratory and stored in a −80℃ refrigerator immediately. Total fecal microbial DNA was extracted using the Fecal Genome DNA Extraction Kit (Catalog No. AU46111−96; BioTeke Corporation, Beijing, China). DNA quantification was performed utilizing Qubit (Invitrogen, USA). 16S rRNA gene amplification and sequencing The V3-V4 hypervariable regions of the bacterial 16S rRNA gene were amplified using bar-coded primers 341F (5’-CCTACGGGNGGCWGCAG-3’) and 805R (5’-GACTACHVGGGTATCTAATCC-3’) [32]. PCR reactions were performed in a total volume of 25 μL containing 12.5 μL of 2 × Phusion High-Fidelity PCR Master Mix (Catalog No. F531L; Thermo Fisher Scientific, Waltham, MA, USA), 0.2 μM each primer, and 10 ng of template DNA. Thermal cycling conditions were as follows: initial denaturation at 98°C for 30 s; 25 cycles of denaturation at 98°C for 10 s, annealing at 54°C for 30 s, and extension at 72°C for 30 s; followed by a final extension at 72°C for 5 min. PCR amplicons were purified using AMPure XT magnetic beads (Catalog No. A63882; Beckman Coulter Genomics, Danvers, MA, USA). Purified amplicons were pooled in equimolar concentrations and paired-end sequenced (2 × 250 bp) on an Illumina NovaSeq 6000 platform (Illumina, Inc., San Diego, CA, USA) by LC-Bio Technology Co., Ltd. (Hangzhou, China). Bioinformatics analysis of 16S rRNA data Raw sequencing data were demultiplexed, and sequencing primers were removed using Cutadapt (version 1.9). Paired-end reads were merged using FLASH (version 1.2.8) with default parameters (minimum overlap = 10 bp, maximum mismatch density = 0.25). Quality filtering was performed using fqtrim (version 0.94) with a sliding-window algorithm (window size = 4, average quality threshold = Q20). Reads shorter than 100 bp or containing more than 5% ambiguous bases (“N”) were discarded. Chimeric sequences were identified and removed using VSEARCH (version 2.3.4) with the “uchime_denovo” algorithm. Amplicon sequence variants (ASVs) were inferred using the DADA2 pipeline (version 1.18.0) within the QIIME2 framework (version 2021.11). Taxonomic assignment of ASVs was performed using the QIIME2 feature-classifier plugin (classify-sklearn naive Bayes taxonomy classifier) against two reference databases: (1) the NT-16S database (Release 20230718; National Center for Biotechnology Information, Bethesda, MD, USA) with thresholds of ≥ 90% identity, ≥ 80% coverage, and E-value ≤ 1e-5; and (2) the SILVA database (Release 138; Max Planck Institute for Marine Microbiology, Bremen, Germany) with a minimum confidence threshold of 0.7. Using QIIME2 and the acquired ASV feature sequences, α and β diversities were computed. Diversity and statistical analyses Alpha diversity (Chao1 and Shannon indices) was calculated using the phyloseq package (version 1.38.0) in R (version 4.3.3). Beta diversity was assessed using Bray-Curtis distance matrices and visualized via principal coordinate analysis (PCoA) using the ade4 package (version 1.7–22). Analysis of similarities (ANOSIM) was performed using distance matrices (Bray-Curtis, Jaccard, weighted and unweighted UniFrac) within QIIME2. The differentially abundant genera were identified using the Wilcoxon signed-rank test with Benjamini-Hochberg false discovery rate (FDR) correction. A genus was considered significantly different if FDR-adjusted p < 0.05. The distances between samples were ranked to determine the within-group and between-group differences, and permutation tests were used to determine the statistical significance of the initial between-group differences. Metabolome sample preparation Fecal samples (50 mg each) were thawed on ice and extracted with 0.5 mL of cold 80% methanol (HPLC grade, Catalog No. 34860; Honeywell, Muskegon, MI, USA) in ultrapure water (Milli-Q, 18.2 MΩ·cm; Merck, Darmstadt, Germany). The mixture was vortexed for 30 s and incubated at −20°C for 30 min, then centrifuged at 20,000 × g for 15 min at 4°C. The supernatant was transferred to a fresh tube and vacuum-dried. Dried extracts were reconstituted in 100 μL of 50% methanol and stored at −80°C until analysis. A pooled quality control (QC) sample was prepared by mixing 10 μL of each extracted sample and analyzed every 10 injections to monitor system stability. LC-MS analysis Chromatographic separation was performed on an UltiMate 3000 UPLC system (Thermo Fisher Scientific, Bremen, Germany) equipped with an ACQUITY UPLC HSS T3 column (100 mm × 2.1 mm, 1.8 μm; Catalog No. 186003539; Waters, Milford, MA, USA) maintained at 40°C. Mobile phase A consisted of 5 mmol/L ammonium acetate and 5 mmol/L acetic acid in water; mobile phase B was acetonitrile. The flow rate was 0.35 mL/min with the following gradient: 0–0.8 min, 2% B; 0.8–2.8 min, linear increase to 70% B; 2.8–5.0 min, increase to 90% B; 5.0–5.5 min, increase to 100% B; 5.5–5.7 min, hold at 100% B; 5.7–7.6 min, decrease to 2% B; and 7.6–10 min, re-equilibrate at 2% B. Mass spectrometry was performed on an Orbitrap Exploris 120 mass spectrometer (Catalog No. BRE725536; Thermo Fisher Scientific, Bremen, Germany) equipped with a heated electrospray ionization (HESI) source operating in both positive and negative ion modes. Full-scan spectra were acquired at a resolution of 70,000 over an m/z range of 70–1050, with an automatic gain control (AGC) target of 3 × 10⁶ and maximum injection time of 100 ms. Data-dependent acquisition (DDA) selected the top three most intense ions for fragmentation at a resolution of 17,500 (AGC target 1 × 10⁵, maximum injection time 80 ms). A quality control (QC) sample, which was made as a pooled combination of all research samples, was examined after every ten sample injections in order to track the stability and repeatability of the LC-MS system during the analytical run. Metabolomics data processing and statistical analysis Raw LC-MS data were converted to mzXML format and processed using XCMS (version 3.18.0) in R (version 4.3.3) for peak detection, alignment, retention time correction, and annotation of isotopes and adducts. Metabolite annotation was performed by matching accurate m/z values and fragmentation patterns against the HMDB (version 5.0) and KEGG (release 2023) databases using CAMERA (version 1.46.0) and metaX (version 1.6.0) packages. Data were normalized by total ion current. Principal component analysis (PCA) was performed using metaX. Partial least squares discriminant analysis (PLS-DA) was performed using the ropls package (version 1.30.0) with 7-fold cross-validation to prevent overfitting; variable importance in projection (VIP) scores were calculated. Differential metabolites were identified using the following criteria: paired samples t-test (on log2-transformed abundance values) with p < 0.05, absolute fold change (FC) ≥ 1.2 (FC ≥ 1.2 for up-regulated metabolites or FC ≤ 0.833 for down-regulated metabolites), and variable importance in projection (VIP) ≥ 1 from PLS-DA. FC was calculated as mean abundance in the HD group divided by mean abundance in the HC group. An FDR was used to adjust the p-value for multiple testing (Benjamini–Hochberg). A nominal p < 0.05 (paired samples t-test) was used as the initial threshold, and Benjamini-Hochberg FDR-adjusted p-values were calculated for multiple testing but not used as a strict inclusion criterion. MetaX was used to do supervised PLS-DA in order to distinguish between the various variables between groups. The VIP value was determined. The selection of significant features was done using a VIP cut-off value of 1.0. Pathway enrichment analysis was performed using the hypergeometric test against KEGG pathways via the clusterprofiler package (version 4.8.0) in R. Receiver operating characteristic (ROC) curves were generated using the pROC package (version 1.15.0) to evaluate diagnostic performance of individual and combined metabolites. We selected the most significant Top 5 of the differential metabolites and drew its separate ROC curve, and calculated the total ROC curve through a logistic regression model. Correlation analysis of microbiome and metabolome Correlation analysis of differential metabolites (FC ≥ 1.2 or FC ≤ 0.833 and p < 0.05 and VIP > 1 from metabolomic analysis) and differential species (p < 0.05 from microbiome analysis) was performed, including Spearman correlation analysis, Mantel test analysis, and differential functional pathway analysis. The Spearman correlation coefficient is a nonparametric measure of rank correlation. The correlation heatmap were drawn based on results of the Spearman correlation analysis (*p < 0.05, **p < 0.01). The Mantel test was an analysis method for determining the correlation between two sets of distance matrices (rather than two sets of variable matrices). Statistical analyses Frequencies and percentages representing categorical data were compared using the chi-square test. Continuous data with or without a normal distribution were compared using means ± standard deviations or medians and interquartile ranges (IQR). Based on our household paired design, the Paired Samples t-test (for normally distributed data) and the Wilcoxon signed-rank test (for non‑normally distributed data) were employed. Statistical power verification. Post-hoc power analysis was performed using the web-based tool for case-control microbiome studies. With a sample size of 96 matched pairs, a two-sided alpha of 0.05, and moderate effect sizes (Cohen‘s d = 0.4–0.5), our study achieved > 85% power to detect the observed differences in gut microbial diversity and differential metabolites. Statistical significance was defined as two-tailed p-values less than 0.05. All statistical analyses were performed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA) and R version 4.3.3 (R Foundation for Statistical Computing, Vienna, Austria). The following R packages were used: phyloseq (v1.38.0), ade4 (v1.7-22), metaX (v1.6.0), ropls (v1.30.0), CAMERA (v1.46.0), pROC (v1.15.0), and clusterProfiler (v4.8.0). Results Patient characteristics S1 Table provides a summary of the baseline characteristics of 96 hemodialysis (HD) patients and 96 healthy controls (HC) at the time of sample collection. Gut microbial diversity between hemodialysis patients and healthy controls We analyzed and compared the microbiomes of 192 fecal samples from 96 hemodialysis patients and 96 healthy controls. To assess the sequencing depth, rarefaction curves were produced; when the curves plateaued, it meant that enough sequencing had been done for a trustworthy analysis. Statistically significant variations between the groups were shown by α-Diversity (S9 Fig). The Chao1 index values for HD were significantly higher (p < 0.001), but the Shannon index revealed a negligible (p = 0.18), diversity-related difference between the two groups. HD patients have higher abundance of gut microbiota than their healthy controls (HC). However, there is no difference in the diversity of gut microbiota. S1 Fig e-f illustrated the differences (β-diversity) in gut microbiota composition among samples from distinct groups, as depicted through unconstrained principal coordinate analysis (PCoA). And analysis of similarities showed that the grouping was statistically significant and reliable (p = 0.001, R = 0.1625). Select the species classification of top 30 abundance, and the composition differences of dominant species between the two groups at the phylum level were shown with a stacked bar chart (S1 Fig). The most in both groups were Firmicutes, and the HD group was higher. Verrucomicrobiota also accounted for more in the HD group. However, the amount of Actinobacteria and Bacteroidota is significantly higher in the HC group. Sankey plots (S2 Fig) showed the species with abundance top10 (genus) and its affiliated phylum information. Both groups account for the largest proportion of Bifidobacterium. And some bacteria were more in the HD group than in HC: Escherichia-shigella, Akkermansia, Streptococcus, Subdoligranulum, and Ruminococcus]_gnavus_group. 51 distinguishing taxon features across various taxonomic levels between the two groups were revealed by the LEfSe analysis (Fig 1). At the level of genus, Ruminococcus, Blautia, Phascolarctobacteriu, Clostridium_sensu_ stricto_1, Lachnospiraceae. Clostridia_UCG − 014_unclassified, Veillonella, and Erysipelato -clostridium were enriched in HD patients. In contrast, HC group demonstrated a higher relative abundance of Dorea, Erysipelotrichaceae_UCG-003, Psychrobacter, Prevotella_9, Megamonas, Dialister, Agathobacter, and Bifidobacterium. Indicator species analysis found species that may serve as biomarkers in different groups (S3 Fig). Obviously, Dialister was considerably enriched in the HC group (p < 0.01), whereas Blautia and Fusicatenibacter were significantly enriched in the HD group. Ruminococcus_gnavus_group, Clostridium_sensu_stricto_1, Phascolarctobacterium, Streptococcus, Roseburia, and Subdoligranulum are also members of the HD group. HC group also enriched with Megamonas, Erysipelotrichaceae_UCG-003, Agathobacter, Prevotella_9, and Bifidobacterium. This is consistent with the statistical results of LEfSe analysis. LDA score showing differentially abundant taxa of the gut microbiota. Differential taxon features identified by LEfSe according to hemodialysis patients and healthy controls after grouping (LDA score > 3, p < 0.05). Yellow and green bars represent taxon features with significantly higher expression in HD and HC groups, respectively. And the length represents LDA score. LDA linear discriminant analysis, LEfSe linear discriminant analysis effect size. Overall metabolomics analysis of fecal samples 192 fecal samples from the HD patients (96) and HC group (96) had their metabolomes analyzed and contrasted. Using R (version 4.3.3), a total of 2275 molecular characteristics were gathered and statistically examined. With an intercept of Q2 = −0.32 and an R2 = 0.67, PLS-DA showed that the HD and HC samples had different distributions, demonstrating the model's dependability and lack of overlifting (Fig. 2). Differential metabolites were filtered based on FC ≥ 1.2 or FC ≤ 0.833, p < 0.05, and VIP ≥ 1, which were then displayed using a heatmap (S4 Fig). When comparing the feces of the HD group to those of the HC group, 497 important metabolites that were involved in the metabolism of amino acids, vitamins, lipids, purines, and pyrimidines were changed. Here we show only the top 20 most significant metabolites (S3 Table). The levels of Imidazoleacetic acid, 4-Pyridoxic acid, N-Methyl-2-pyridone-5-carboxamid, PE(P-18:0/18:1(9Z)), Adenosine, Pyridoxal hydrochrolide, D-Arabinose-5-phosphate disodium salt, PG 30:0, and PG(15:0/16:0) were increased in fecal samples of HD. Whereas, the levels of Ascorbic acid, Prostaglandin D2, Dl-Pipecolinic acid, Biotin, D-Xylose, 5-Methoxyindole-3-acetic acid, Pimelic acid, L-Aspartate, Picolinic acid, Orotic acid, and N-acetylputrescine hydrochloride were decreased in HD (Fig 3). Partial least squares discriminant analysis (PLS-DA) of fecal metabolomics data from hemodialysis patients and healthy controls. The blue dots represented HD patients and the red dots represented healthy controls in the two-dimensional PLS-DA score plots (a). R2 regression line is red, Q2 regression line is blue (b). If the R² regression line lies above the Q² line and the y-intercept of the Q2 regression line is less than 0, the model can be considered free from overfitting. Overall distribution of differential metabolites in hemodialysis patients and healthy controls. Volcano plots were drawn for all metabolites in differential expression analysis. Red represented upregulated significantly differentially expressed metabolites, blue represented downregulated, and gray dots represented non-significantly differentially expressed metabolites. Metabolic pathway analysis To identify biologically significant patterns within fecal metabolomics data, pathway analysis was conducted utilizing the KEGG metabolic database in conjunction with the Hypergeometric test (p < 0.05). The top20 perturbed metabolic pathways ranked with p-values are shown in a bubble plot (S5 Fig). The rich factor results showed that the Glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway had the greatest enrichment degree. The second is Cholesterol metabolism pathway. The pathway of Autophagy, Glycerophospholipid metabolism, Bile acid and Bile secretion, Sphingolipid signaling pathway, digestion and absorption of protein and vitamin, and Tryptophan metabolism also differed in the fecal samples between the two groups. Metabolite diagnostic performance After proving that metabolomics is essential for differentiating HD patients from HC controls, we looked into possible HD diagnostic biomarkers. For a preliminary evaluation of their diagnostic performance, the top five metabolites with the highest significant p-values were chosen for conventional univariate receiver operating characteristic (ROC) curve analysis. 4-Pyridoxic acid, N-Methyl-2-pyridone-5-carboxamide (Nudifloramide), imidazoleacetic acid, ascorbic acid, and tocopheronic acid had respective area under the curve (AUC) values of 0.888, 0.799, 0.927, 0.806, and 0.891. Fig 4 displayed the metabolites’ and the combined model's corresponding ROC curves. 4-The sensitivity and specificity of pyridoxic acid were 83.33% and 84.37%, respectively, with an AUC of 0.888 (95% CI: 0.834–0.929) (Fig 4a). N-Methyl-2-pyridone-5-carboxamide had a sensitivity of 76.04%, a specificity of 78.12%, and an AUC of 0.799 (95% CI: 0.735–0.853) (Fig 4b). According to Fig 4c, the imidazoleacetic acid had an AUC of 0.927 (95% CI: 0.881–0.960), a sensitivity of 95.83%, and a specificity of 85.42%. According to Fig 4d, the ascorbic acid had an AUC of 0.806 (95% CI: 0.742–0.859), a sensitivity of 70.83%, and a specificity of 82.29%. According to Fig 4e, the tocopheronic acid had an AUC of 0.891 (95% CI: 0.838–0.931), a sensitivity of 96.87%, and a specificity of 75%. The illness results in simultaneous changes to several metabolites. To more accurately forecast the biomarker's value, we compute the overall AUC value of these target metabolites using the logistic regression model. The combined model yielded a p < 0.001, a sensitivity of 90.62%, a specificity of 87.5%, and an AUC of 0.935 (95% CI: 0.890–0.965) (Fig 4f). ROC analysis of potential biomarkers for differentiating hemodialysis patients from healthy controls. 4-Pyridoxic acid showed an AUC of 0.888 (95% CI: 0.834-0.929, p < 0.001) (a); the N-Methyl-2-pyridone-5-carboxamide presented an AUC of 0.799 (95% CI: 0.735-0.853, p < 0.001) (b); Imidazoleacetic acid presented an AUC of 0.927 (95% CI: 0.881-0.960, p < 0.001) (c); Ascorbic acid presented an AUC of 0.806 (95% CI: 0.742-0.859, p < 0.001) (d); Tocopheronic acid presented an AUC of 0.891 (95% CI: 0.838-0.931, p < 0.001) (e); the combined model performed an AUC of 0.935 (95% CI: 0.890-0.965, p < 0.001) (f). *The data were not normally distributed, therefore the paired Wilcoxon signed-rank test was employed. Combined analysis of metabolomics and gut microbiomes We used Spearman correlation analysis on the differential genus and differential metabolites of the HD group vs HC group from microbiome and metabolomics study to further investigate the connection between gut microbial flora and host metabolic phenotype. Correlation heatmap between differential genus and differential metabolites showed that the most relevant ones were Ruminococcus and 5,8,11-Etycotriolic acid (ETI), and Ruminococcus and Docosapentoic acid (DPA). Secondly, related to Ruminococcus is Adrenic Acid, 13-EPAHAAB (EPA), and Tryptamine (S6 Fig). The correlation network among differential genera and metabolites is shown in S7 Fig. We also use the Mantel test to determine the correlation between the two sets of distance matrices (S8 Fig). The network diagram indicated that the correlation between Glucerabacte and Naphthalenecarboxae is the most significant, and it is negatively correlated (r < −0.5). Among the other metabolites, the metabolites with the most correlation with the gut microbiota species were 1-Palmitoyl-2-linoleoyl PE and 1-Methyladenine. Comparing the functional pathways with statistical differences in microbiomics and metabolomics, it was found that the differential functional pathways shared by the two omics were as follows: Bile secretion, Caffeine metabolism, Gastric acid secretion, and Vitamin B6 metabolism. Discussion Chronic kidney disease, a growing public health concern, substantially reduces the nutritional status of patients [33]. We carried out a 1:1 paired design under the same diet and living conditions and ruled out age and gender distractions. We revealed the differential microbiota, differential metabolites, and differential functional pathways between hemodialysis (HD) and healthy controls (HC), and we explored potential connections between the two omics. Changes in the species and distribution of intestinal flora can be defined as gut dysbiosis [34]. We observed that gut microbial richness was significantly different between hemodialysis patients (HD) and healthy controls (HC). On average, HD patients demonstrated higher microbial richness and diversity than HC group. In particular, we discovered that the relative abundance of two beneficial bacteria for humans, Actinobacteria and Bacteroidota [35–36], was significantly lower in HD than in HC. This suggests that certain taxonomic configurations of the human gut microbiota may represent health-related alterations associated with hemodialysis. Numerous intestinal and extraintestinal conditions, including CKD, obesity, hypertension, and inflammatory bowel disease, have been linked to decreased gut microbial diversity [37–41]. Notably, new metabolomics studies have shown that specific gut-derived uremic toxins are highly and positively linked with gut microbial diversity, despite the fact that a more diverse microbial community is frequently thought to reflect a healthy host-microbiome connection [42–43]. Thus, our results have higher richness in HD, which may be due to the increase in certain toxins and pathogenic bacteria. For example, excessive proliferation of Firmicutes may lead to metabolic imbalance; Clostridium_sensu_stricto and Erysipelato-clostridium as pathogenic bacteria can increase the infection risk in HD patients [44–46]. Blautia can maintain the integrity of the intestinal mucosa and regulate intestinal immune function [47–48]. Blautia and Fusicatenibacter can serve as biomarkers to distinguish HD patients from healthy individuals. Bifidobacterium and Prevotella were beneficial bacteria [49–50], especially in the HC group, our results corroborate previous findings. Hence, in the context of HD, extensive and comprehensive omics research is needed to deepen our comprehension of the intricate relationships between microbial diversity and host health. It was feasible to differentiate HD patients from healthy controls in this study because to the chemical profiles of the fecal samples. Following screening, it was discovered that the HD and HC groups had significantly different levels of 497 fecal metabolites. Compared to healthy controls, HD patients had disturbed metabolisms of amino acids, vitamins, lipids, purines, and pyrimidines in connection to dialysis. Certain amino acid levels were changed in HD patients, and the elevated imidazoleacetic acid is a byproduct of histidine metabolism; And those that have been decreased are: Dl-pipecolinic acid, L-Aspartate, and Picolinic acid, they are involved in lysine metabolism, tricarboxylic acid cycle (TCA), and tryptophan metabolism, respectively. This is consistent with Lanzon B's conclusion [51]. In an animal experiment on intestinal flora and metabolites in the development of chronic kidney disease, Liu et al. [52] found that metabolites that were differentially abundant in feces were mainly linked to tyrosine metabolism, histidine metabolism, and the biosynthesis of tryptophan and phenylalanine. Additionally, Thalacker-Mercer's review [53] demonstrated that pathologic circumstances [such as chronic kidney disease (CKD) and chronic obstructive pulmonary disease (COPD)] result in a decrease in circulating amounts of histidine. Pyridoxal hydrochloride and 4-Pyridoxic acid participate in the metabolic process of vitamin B6, and N-Methyl-2-pyridone-5- carboxamide is a metabolite of vitamin B3. Both of these are higher in the HD group. However, Ascorbic acid (Vitamin C) and Biotin (Vitamin B7) were lower than HC group. A deficit of vitamin B6, a rate-limiting coenzyme that is crucial for the production of heme, is frequently observed in patients with chronic renal disease, especially those who need dialysis and after receiving erythropoietin-stimulating agent (ESA) [54]. Kumakura et al. [55] discovered that nicotinamide (B3) can foster the production of adenosine triphosphate (ATP), and reduce kidney inflammation and fibrosis. Dialysis patients frequently have vitamin C shortage, which can be caused by increased vitamin C catabolism in vivo from inflammation, limited consumption of foods high in vitamin C, and dialytic vitamin C clearance [56]. Biotin, a water-soluble vitamin, is crucial as one of the coenzymes in energy production, according to Fujiwara M's study [57]. HD-related cramps may be caused by a biotin deficiency, and biotin's coenzyme actions are hampered by accumulating biotin metabolites. Vitamin B6 and B3 metabolism were active in HD patients. Conversely, vitamin C and biotin metabolism are lower. Moreover, PG(16:0/18:1(9Z)), PG 30:0, and PG(15:0/16:0), as isomers of phosphatidylglycerol (PG), were increased to maintain cell membrane stability and to participate in signaling [13,58]. Adenosine can participate in ATP synthesis and inhibit inflammatory responses, which also increase in HD. The primary potential biomarkers of HD (4-Pyridoxic acid, Nudifloramide, Imidazoleacetic acid, Ascorbic acid, and Tocopheronic acid) found by ROC analysis also confirmed the above important differential metabolites. We observed metabolic dysregulation with certain metabolic pathways in fecal samples of HD patients, mainly Glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway, and the pathway of Autophagy, Cholesterol metabolism, Glycerophospholipid metabolism, Bile acid and Bile secretion, Sphingolipid signaling, digestion and absorption of protein and vitamin, and Tryptophan metabolism. GPI-anchored proteins play an important role in cell recognition, signal transduction and immune response, involving a series of enzymatic reactions [59]. Cholesterol is converted into bile acids in the liver through hydroxylation, oxidation and binding reactions, which together regulate the balance of cholesterol metabolism. The metabolism of tryptophan includes the production of kynurenine and other metabolites, the results suggested that the metabolism of the kynurenine pathway may be a significant factor in hemodialysis and a possible target for treatment in HD patients [60–61]. Additionally, the digestion and absorption of proteins and vitamins in the intestine, intestinal autophagy pathway, and the metabolism of glycerophospholipids were all abnormal in HD group. Hence, these highlighted metabolites play an important role in physiological processes such as amino acid metabolism, energy metabolism, nucleic acid synthesis, immune regulation and antioxidant defense. Their metabolic pathways and physiological functions reflect the complex metabolic networks and regulatory mechanisms in the human body. Based on the correlation analysis of microbiota and metabolomics, of important note, the most relevant combination were Ruminococcus and Etycotriolic acid (ETI), Ruminococcus and Docosapentoic acid (DPA), and Ruminococcus and 13-Epahaab (EPA). Ruminococcus is a member of the Firmicutes family, which ferments dietary fiber and generates metabolites such short-chain fatty acids (SCFA). According to Lin TY's study [62], the dialysis group with decreased mortality had increased expression of two SCFA-producing bacteria, Succinivibrio and Anaerostipes. SCFAs have been shown to have a variety of effects on host physiology, such as anti-inflammatory qualities and the preservation of gut integrity [63]. Omega-3 fatty acids, such as DPA and EPA, are known to have anti-inflammatory and hypotriglyceridemic effects, but their dietary equivalents have been shown to have pro-inflammatory qualities [64]. ETI is also a regulator of lipid metabolism. Ruminococcus has a clear metabolic association with 3 differential metabolites, which may affect health through regulating lipid metabolism and immunomodulation and anti-inflammatory synergistic effects [65]. The differential functional pathways of HD vs HC were identified from microbiome and metabolomics, respectively. However, the following pathways are mutual to both groups: Bile secretion, Caffeine metabolism, Gastric acid secretion, and Vitamin B6 metabolism. This is consistent with our KEGG pathway enrichment conclusion. Through reasonable thinking, HD patients are often accompanied by abnormal liver function, which indirectly affects bile secretion, and dialysis will cause slowed caffeine metabolism and reduce the efficiency of metabolic waste removal. Dialysis dietary restrictions may lead to insufficient vitamin B6 intake, and uremia toxins may interfere with the activation and utilization of vitamin B6. Similarly, uremia toxins may damage the gastric mucosal barrier, leading to abnormal gastric acid secretion [66–67]. Innovations First, the 1:1 household-paired design is a key innovation. Unlike most previous studies, which did not control for diet or living conditions (major confounders of gut microbiota), we matched each HD patient with a cohabiting HC under the same diet. This minimizes confounding and allows us to attribute observed differences to HD itself rather than lifestyle factors. Second, we performed an integrated analysis of the fecal microbiome and metabolome, a more comprehensive approach than previous studies that relied on 16S sequencing or serum metabolomics alone. This allowed us to identify shared functional pathways across both omics layers, a cross‑omics convergence rarely reported in HD patients. Third, the fecal biomarkers we identified achieved high diagnostic accuracy (AUC up to 0.927). They are non‑invasive and directly reflect gut microbial metabolism, offering practical advantages over serum‑based markers for screening and monitoring, though external validation is still needed. Clinical translation feasibility Our biomarkers are fecal, not serum. This makes collection non‑invasive and easy for patients to do at home, which supports repeated testing. Fecal markers also directly reflect gut microbial activity, whereas serum markers capture mixed host‑microbial metabolism after absorption. However, fecal markers come with challenges. Stool consistency, transit time, and sampling can cause variability. The current LC‑MS method is not routine in most labs and is relatively costly. A more practical next step would be to develop targeted assays, such as ELISA or point-of-care kits. This still requires external validation. Our results suggest that vitamin B6, B3, C, and biotin supplementation might help restore metabolic balance, while increasing dietary fiber could support Bifidobacterium and short‑chain fatty acid(SCFA) production. We could also consider using possible probiotics, such as Bifidobacterium. These strategies aim to counter the observed dysbiosis and metabolic shifts, but need validation specifically in HD patients. Our study has several strengths. To the best of our knowledge, this is the first published report to select a healthy control group according to the same diet and living conditions for a 1: 1 matched case- control study in the hemodialysis population. We have advanced amplicon sequencing and state-of-the-art metabolomics platform, and we perform rigorous statistical analysis based on a sufficient sample size. In addition to analyzing the microbiome and metabolome separately, we also analyzed multi-omic correlations. There are various limitations to our investigation. First, due to the observational design, our findings cannot indicate causal links. Second, only baseline fecal samples were taken. However, since microbial diversity may decrease with time in HD patients, a higher baseline microbial diversity could bias the study results in favor of the null hypothesis. Third, the long‑term effects of past antibiotic use on gut microbiota cannot be fully excluded. Fourth, limited by the depth and scope of the study, we have not yet conducted in-depth research on the underlying mechanisms that affect the disease process and prognosis of patients. We also acknowledge several technical limitations. Using 16S rRNA sequencing instead of shotgun metagenomics limited species level resolution and functional prediction. The absence of serum metabolomics means we cannot directly connect fecal changes to the host's systemic metabolic status. Since all participants came from Hebei Province, our findings may not generalize to other regions. In the future research process, it is imperative to further delve into the characteristic profiles of the gut microbiome and gut metabolome in HD patients, explore their potential value as diagnostic markers, and use this as an entry point to explore possible therapeutic intervention targets. This is a highly prospective and important future direction. Conclusion In this study, we employed a household-paired design (HD patients and cohabiting healthy controls sharing the same diet and living environment) combined with 16S rRNA sequencing and fecal metabolomics. The main conclusions are as follows: First, HD patients exhibited higher gut microbial richness (Chao1 index) but no significant difference in Shannon diversity compared with controls, with enrichment of Ruminococcus and depletion of Bifidobacterium. Second, A total of 497 fecal metabolites were significantly altered in HD patients, predominantly involving amino acid, vitamin, and lipid metabolism. Third, Integrated multi-omics analysis revealed correlations between specific gut bacteria and metabolites, and identified four shared dysregulated functional pathways: Bile secretion, Caffeine metabolism, Gastric acid secretion, and Vitamin B6 metabolism. Fourth, The fecal metabolites 4-pyridoxic acid, imidazoleacetic acid, and ascorbic acid showed high diagnostic accuracy and may serve as non‑invasive candidate biomarkers for HD. Practical application It is meaningful to delve into the characteristic profiles of the gut microbiome and gut metabolome in HD patients, explore their potential value as diagnostic markers, and use this as an entry point to explore possible therapeutic intervention targets. To further our knowledge of the intricate relationships between human health and microbial diversity in the context of CKD, integrated multi-omics research is also necessary. This is a highly prospective and significant future direction. Supporting information Characteristics of the study population. Clinical data of hemodialysis patients and baseline information of the two groups. (PDF) Intake of major nutrients between hemodialysis patients and healthy controls. The average intake of major nutrients in both groups, and there were no significant differences in nutrient intake between the two groups. (PDF) Fecal identified differential metabolites between hemodialysis patients and healthy controls. Metabolites with significant differences between the two groups and their corresponding metabolic pathways. (PDF) The phylum-level taxonomic display of the Hemodialysis patients and Healthy controls. We selected the Top 30 phylums of abundance. The horizontal axis is grouped, and the vertical axis represents the relative abundance of a certain species classification. Different colors correspond to different phylums. (PDF) Comparison of the abundance of gut microbiota in hemodialysis patients and healthy controls at the phylum and species level. The figure shows: grouping (left), the abundance of the corresponding phylum level (middle) and genus level (right). Different colors correspond to different species. (PDF) Indicator Species Analysis between different groups. The size of the point represents the sqrtIVt value, and the larger the point, the more the ASV can be used as a biomarker. The color represents the p-value. sqrtIV: square root result of indicator value, used to compare the correlation between microbiota and treatment groups. (PDF) Metabolic patterns in hemodialysis patients and healthy controls. Fecal metabolite profiles in hemodialysis patients and healthy controls were shown as heatmaps. Each row represented data for a differentially expressed metabolite and each column represented an individual. Different colors corresponded to the different relative abundance of metabolites. Red and blue colors represented increased and decreased levels of metabolites, respectively. (PDF) Pathway analysis of altered metabolites isolated from HD patients compared with healthy controls. Rich Factor: the number of differential metabolites located in the Pathway / the total number of metabolites contained in the Pathway. The size of the dot represented the number of differential metabolites on the pathway. The color of the dot represented the p-value of the enrichment analysis, that is, the significance of the enrichment. (PDF) Correlation heatmap of differential species and metabolites between hemodialysis patients and healthy controls. Color represented correlation, red represented positive correlation, and blue represented negative correlation. The darker the color, the stronger the correlation. *: p < 0.05,**: p < 0.01. (PDF) Correlation network of differential species and metabolites between hemodialysis patients and healthy controls. Green triangles represent bacterial genera; purple circles represent metabolites. Solid lines indicate positive Spearman correlations (p < 0.05), dashed lines indicate negative Spearman correlations (p < 0.05). Only statistically significant correlations are displayed. (PDF) Mantel test network heatmap between differential genus and metabolites. The heatmap on the right: the redder the color, the closer the correlation coefficient (r) is to 1. Conversely, the bluer the color, the closer the r-value is to −1. The network diagram in the lower left corner: the color represented the p-value, and the thicker the line, the stronger the correlation. (PDF) Alpha diversity analysis and Beta diversity analysis between hemodialysis patients and healthy controls. i (PDF) 2 Mar 2026 Dear Dr. Di, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 16 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Hongtao Bi, Ph.D. Academic Editor PLOS One Journal Requirements: 1. When submitting your revision, we need you to address these additional requirements.-->--> -->-->Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at -->-->https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and -->-->https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf-->--> -->-->2. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.-->--> -->-->3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. -->--> -->-->When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.-->--> -->-->4. Thank you for stating in your Funding Statement: -->-->This work was supported by Hebei Provincial Health Commission and Department of Finance of Hebei Province (2024 Government-Sponsored Outstanding Medical Talent Program, No.ZF2024069) -->--> -->-->Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. -->-->Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.-->--> -->-->5. Thank you for stating the following financial disclosure: -->-->This work was supported by Hebei Provincial Health Commission and Department of Finance of Hebei Province (2024 Government-Sponsored Outstanding Medical Talent Program, No.ZF2024069) -->--> -->-->Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." -->-->If this statement is not correct you must amend it as needed. -->-->Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.-->--> -->-->6. Thank you for stating the following in your Competing Interests section: -->-->I have read the journal's policy and the authors of this manuscript have the following competing interests: [The authors have declared that no competing interests exist] -->--> -->-->Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now -->-->This information should be included in your cover letter; we will change the online submission form on your behalf.-->--> -->-->7. In the online submission form, you indicated that “The data underlying this article are available in the article and in its online supplementary material. Most of the data has been shown in the form of figures and tables in the article. The anonymized microbiome and metabolome datasets are available to other researchers upon request.” -->-->All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either a. In a public repository, b. Within the manuscript itself, or c. Uploaded as supplementary information.-->-->This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval.-->--> -->-->8. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.-->--> -->-->9. Please upload a new copy of Figures 1 to 4, S4, S6, S7 and S8, as the detail is not clear. Please follow the link for more information: https://journals.plos.org/plosone/s/figures-->--> -->-->10. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.-->--> -->-->11. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. ?> Additional Editor Comments: This manuscript employs an integrated multi-omics approach combining 16S rRNA gene sequencing and untargeted fecal metabolomics to conduct a 1:1 matched case-control study investigating the characteristics of gut dysbiosis in hemodialysis (HD) patients, with HD patients and cohabiting healthy controls (HC) sharing identical dietary and living conditions enrolled as the study subjects. The clinical question addressed by this study is of critical importance: the crosstalk between the gut microbiome and metabolome is closely associated with adverse clinical outcomes in HD patients, and the paired design adopted in this study effectively controls for diet, the most prominent confounding factor in gut microbiome research. The study has a relatively sufficient sample size (96 HD-HC matched pairs) and a rigorous multi-omics analytical workflow. A total of 4 peer reviewers were invited to evaluate this manuscript during the review process. Reviewer 1 highly recognized this study, stating that the work has a rigorous design, reliable multi-omics methodology, and promising findings regarding the identified biomarkers, and recommended direct acceptance without revisions. However, Reviewers 2, 3, and 4 all raised multiple critical concerns, covering fundamental errors in epidemiological data and calculation formulas, inconsistent descriptions of the study design, insufficient methodological details, logical inconsistency between the introduction and study results, inadequate elaboration of innovation and clinical translation value, missing data visualization figures, and incomplete disclosure of study limitations, among other aspects. As the Academic Editor handling this manuscript, I have comprehensively evaluated the full text of the manuscript and all reviewer comments. I confirm that this study has scientific value and clinical relevance, but there are major flaws in academic rigor, methodological accuracy, and content completeness, which must be fully addressed through a major revision. 1. Correction of the Accuracy of Core Data and Epidemiological Statements (1) Correction of prevalence data for hemodialysis patients The statement in the manuscript that "the number of HD patients in China had reached 8.44 million by the end of December 2022" has a fundamental deviation from authoritative epidemiological data. As pointed out by Reviewer 3, this figure corresponds to the total prevalence of chronic kidney disease (CKD) in China, not the number of patients receiving maintenance hemodialysis. The authors must recheck the data from authoritative sources, including the China Kidney Disease Network (CK-NET) Annual Report and the National Medical Quality Report on Kidney Diseases issued by the National Health Commission of the People’s Republic of China, revise this figure, clearly distinguish between the total CKD population and maintenance hemodialysis patient population, and provide valid peer-reviewed references to support the revised data. (2) Correction of the overgeneralized statement on renal replacement therapy modalities The claim in the manuscript that "hemodialysis accounts for nearly 90% of patients receiving renal replacement therapy in most countries" is inaccurate and overly generalized, as the distribution of dialysis modalities varies significantly across countries, regions, and healthcare systems. The authors must revise this statement, provide region-specific data supported by appropriate references, or add rigorous qualifiers to avoid overgeneralization. (3) Correction of errors in key calculation and statistical formulas The reversed BMI calculation formula on Line 139 of the manuscript is a serious and unacceptable error in epidemiological research. The authors must immediately correct the formula to: Body Mass Index (BMI) = weight (kg) / height² (m²). In addition, as noted by Reviewer 2, the authors must conduct a comprehensive review of all statistical formulas, descriptions of fold-change (FC) thresholds, and screening criteria for differential features in the manuscript, correct all errors, and ensure 100% consistency between the methodological description and the actual analytical workflow. 2. Resolution of Core Issues in Study Design and Methodology (1) Elimination of contradictory descriptions of the study type The manuscript simultaneously describes the study as both a "prospectively recruited matched case-control study" and a "retrospective study", which constitutes a fundamental contradiction that directly affects the level of evidence and ethical compliance of the study. The authors must explicitly define the study type: If it is a retrospective study: Supplement full details of the retrospective design, the time frame of data collection, and the approval status of the waiver of informed consent by the ethics committee (if applicable). If it is a prospective case-control study: Delete all references to "retrospective study" in the manuscript, supplement full details of the prospective recruitment process and the implementation of inclusion and exclusion criteria, and ensure completely consistent description of the study type throughout the manuscript. (2) Supplementation of details on the matching strategy and confounding factor control As pointed out by Reviewer 3, the description of the 1:1 matching strategy is overly vague. The authors must supplement the following content in the Materials and Methods section: Additional matching variables beyond age (±2 years) and sex, as well as the rationale for selecting the paired design; The rationale for selecting paired statistical tests (paired t-test / Wilcoxon signed-rank test), and the results of statistical power verification for the paired design; The specific method of dietary assessment (e.g., 3-day 24-hour dietary recall method, food frequency questionnaire), the time frame of dietary monitoring, and the statistical results verifying dietary homogeneity between cohabiting HD-HC pairs, to validate the core advantage of the study design and address the reviewers’ concerns about the effectiveness of dietary control. (3) Improvement of methodological transparency and reproducibility Correct grammatical errors in the description of the study design, supplement complete information (manufacturer, catalog number, and country of origin) for all reagents and instruments, and ensure that the full analytical workflow for 16S rRNA sequencing and metabolomics is described in sufficient detail to support independent replication of the experiment by other researchers, in compliance with the transparency requirements of PLOS ONE. 3. Revision of Academic Expression and Logical Consistency Across All Manuscript Sections (1) Introduction Section Resolve the logical contradiction between the introduction and study results: The current statement in the introduction that HD patients "have a dramatic decrease in gut microbial diversity" is directly inconsistent with the study findings (significantly higher Chao1 index in the HD group, no difference in the Shannon index). The authors must revise this statement, systematically summarize inconsistent conclusions on gut microbial diversity in HD patients from published studies, and refine the study hypothesis, rather than presenting "reduced diversity" as an established conclusion. Strengthen the clinical theoretical rationale for the study: As recommended by Reviewer 3, supplement published research evidence linking gut microbiome alterations in HD patients to adverse clinical outcomes (including mortality, cardiovascular events, malnutrition, and inflammation), to fully demonstrate the clinical importance of this study. Correct non-standard academic expressions: Replace "quantity" with "number", rewrite the study objectives, remove academically weak phrases such as "attempted and new insight", and adopt the rigorous expression recommended by Reviewer 2 to clearly define the primary and secondary endpoints of the study. (2) Results Section Correct all group nomenclature errors: Uniformly replace "healthy families" with "healthy controls (HC)", revise "HC patients" to "HD patients", and ensure consistent group nomenclature throughout the manuscript to avoid reader confusion. Conduct a comprehensive review of the accuracy of all data, statistical values, and p-values in the Results section, to ensure full consistency between the main text, figures, tables, and supplementary materials. (3) Conclusion Section Restructure the conclusion as recommended by Reviewer 2: Avoid restating detailed content from the Discussion section, concisely summarize 3-4 core findings of the study, highlight the methodological strengths and innovation of the work, provide clear implications for clinical practice, and ensure that all conclusions are strictly based on the study data without overinterpretation. 4. Comprehensive Elaboration of Innovation, Clinical Translation Value, and Study Limitations (1) Clear elaboration of the study’s innovation The authors must add a dedicated subsection in the Discussion to explicitly address the questions raised by Reviewer 4, including: Whether the paired design under shared dietary and living conditions is the core innovation of the study, and its advantages over previously published studies; The innovation of the multi-omics integration analysis in this study, especially its advancement to the field compared with previous single-omics studies, in terms of microbiome-metabolome interactions and shared differential pathways; The advantages of the diagnostic biomarkers identified in this study over previously reported markers related to HD patients. (2) Analysis of the clinical translation feasibility of the biomarkers Explicitly state that the markers identified in this study are fecal markers, and supplement the advantages and limitations of fecal markers compared with systemic (serum) markers in the clinical practice of HD. As requested by Reviewer 4, detail the feasibility of applying these markers in routine HD clinical practice, including the accessibility of detection methods, cost, convenience of specimen collection, and the clinical value of their diagnostic performance. (3) Supplementation of potential intervention strategies Add a dedicated paragraph in the Discussion section to discuss potential intervention strategies for gut dysbiosis in HD patients (including probiotics, vitamin supplementation, and dietary modulation) based on the differential bacteria, metabolites, and pathways identified in this study, to enhance the clinical guidance value of the work. (4) Comprehensive and objective statement of study limitations As required by Reviewer 4, the authors must comprehensively supplement the limitations of this study in the dedicated limitations subsection of the Discussion, including but not limited to: The cross-sectional study design cannot establish a causal relationship between gut microbiome alterations and HD status; The use of 16S rRNA sequencing rather than shotgun metagenomic sequencing limits the species-level taxonomic resolution and functional annotation capability; The lack of serum metabolomics data prevents the association of fecal microbiome and metabolome alterations with the host’s systemic metabolic status; The geographical limitation of the multi-center cohort (all centers located in Hebei Province, China) restricts the generalizability of the study findings; The identified diagnostic biomarkers lack validation in an external cohort; Other limitations, including the inability to fully exclude the long-term effects of prior antibiotic use, and single-timepoint sampling that cannot capture the dynamic changes of the gut microbiome and metabolome. 5. Supplementary Requirements for Figures, Tables, and Data Visualization (1) Based on the results of Spearman correlation analysis, add a correlation network diagram illustrating the interactions between differential gut bacterial genera and differential metabolites, with clear annotation of correlation coefficients and statistical significance. (2) Add a heatmap of significantly altered metabolites (core differential metabolites) to visually demonstrate the differences in metabolic profiles between the HD and HC groups. (3) Conduct a comprehensive review of all existing figures and tables: correct spelling errors (e.g., revise "hemodiaylsis" to "hemodialysis"), ensure complete legends and abbreviation annotations, standardized labeling of statistical values, and explicit in-text citations for all figures and tables. Ensure that all supplementary figures and tables have complete annotations and fully correspond to their citations in the main text. 6. Standardization of Ethical Approval, Funding, and Data Availability Statements (1) Ethics Statement: As requested by Reviewer 3, supplement complete details of ethical approval, including the full name of the ethics committee, approval number, type of consent obtained from participants (written informed consent), and a clear statement on whether a waiver of informed consent was granted (accompanied by the ethics committee’s approval document if applicable). (2) Data Availability Statement: Revise the statement to comply with the open data policy of PLOS ONE. The authors must deposit the raw 16S rRNA sequencing data in a public repository (e.g., NCBI Sequence Read Archive (SRA), ENA, DDBJ), and the raw metabolomics data in a specialized metabolomics database (e.g., MetaboLights, Metabolomics Workbench). The dataset accession numbers must be provided in the revised manuscript to ensure unrestricted public access to all underlying data. (3) Competing Interests Statement: Ensure that the competing interests statement is consistent with the content in the submission system, and explicitly declare that no authors have relevant competing interests to disclose. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: No Reviewer #3: Yes Reviewer #4: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: No ********** Reviewer #1: This is an impressive study. The use of multi-omics (combining microbiome and metabolome data) gives a very detailed view of the health of hemodialysis patients. I particularly appreciate the study design—matching patients with healthy controls under similar dietary conditions is excellent and makes your results much more reliable. The identification of specific biomarkers with high accuracy (AUC > 0.8) is a very promising finding. I have no changes to request. This is a high-quality contribution to the field. Reviewer #2: Integrated Multi-Omics Reveals Dysbiosis in Hemodialysis Patients: A Multi-Center Study INTRODUCTION STRENGTHS 1. It has a clear and appropriate opening which is coherent and well structured. 2. On line 1033-104, the research gap is clearly stated. WEAKNESSES 1. On line 75, The wording “quantity” is not appropriate academic language. Kindly replace it with “NUMBER”. 2. On line 84-86, The introduction presents decreased diversity as established, but the results later differ. The introduction does not acknowledge inconsistency. I recommend you change “have a dramatic decrease in gut microbial diversity” to “Have reported alterations in gut microbial activity”. 3. On line 113-115, there is a vague statement that needs to be reconstructed “Attempted and new insight” are weak academically. Kindly rephrase it like: “We aimed to evaluate differences in gut microbial diversity, fecal metabolites, and metabolic pathways between HD patients and healthy controls, and to examine correlations among microbial species, metabolites, and functional pathways.” MATERIALS AND METHODS STRENGTH 1. The study design is clearly described, and variables are clearly matched and stated. 2. On line 122-124, confounders are well controlled. 3. The method is very transparent. WEAKNESS 1. On line 117-118, there is a grammatical error “We conducted a 1:1 matched case-control study that hemodialysis (HD) patients were paired with healthy controls (HC)” I recommend you construct it as: “We conducted a 1:1 matched case-control study in which hemodialysis (HD) patients were paired with healthy controls under…. 2. On line 130, it was stated “For this retrospective study” But earlier description stated an active recruitment and matching. Kindly clarify and be consistent in wording. I recommend “IF Retrospective rephrase earlier sentence to match with the description. IF NOT Kindly remove the word “Retrospective”. 3. On Line 139, “The body mass index, or BMI, was calculated by dividing the height squared (m2) by the weight (kg)”. You have reversed the calculation BMI=weight (kg) /Height in Meters squared BMI = weight (kg) / height² (m²) Not the other way round as you stated it. In general, the methods have some critical issues that need to be fixed, BMI formula incorrect, Fold- change threshold (first location line 229-232, second location (254-255)) is incorrect, kindly rectify that. RESULTS Strengths 1. The results were clearly reported, clearly confirmation of matching. 2. P-value is appropriately reported. 3. There is a multi-level taxonomic interpretation. Weaknesses 1. On line 285, Kindly replace “healthy families” with “healthy controls” because at some points controls were described as health controls, which makes the group description incorrect. 2. On line 314, “192 fecal samples from the HC group (96) and HC patients (96) … Both groups labeled HC, second should be HD. CONCLUSION STRENGTHS 1. The main findings are clearly summarized and aligned with results. 2. On line 439-441, Novelty is reinforced. 3. On line 441-443, The findings are connected to clinical implications WEAKNESSES 1. ON LINE 436-444, conclusion should provide some takeaways, not to restate discussion-level explanations. 2. Conclusion misses opportunity to highlight methodological strengths already presented in manuscript. Reviewer #3: The study titled “Integrated Multi-Omics Reveals Dysbiosis in Hemodialysis Patients: A Multi-Center Study” by Zhang et al. addresses an important and timely topic. However, I recommend that the authors make the following edits to improve their manuscript. 1. Page 12, Lines 73-78: The reported number of hemodialysis patients in China (8.44 million) appears implausibly high. Available epidemiological data suggest that the number of patients on dialysis is more likely in the hundreds of thousands rather than millions. The authors should recheck this figure and ensure that the statistic is accurate, or clarify whether this number refers to a broader population (e.g., total CKD prevalence) rather than patients receiving hemodialysis. 2. Page 12, Lines 73-78: The statement that hemodialysis accounts for nearly 90% of patients receiving renal replacement therapy “in most countries” is overly broad not accurate, as the distribution of dialysis modalities varies significantly by region and healthcare system. The authors should revise this statement to be more specific, either by providing region-specific data or qualifying the claim with appropriate references. 3. Pages 12-13, Introduction Section: The introduction would benefit from a stronger rationale for studying gut dysbiosis specifically in hemodialysis patients. The authors should expand this section by emphasizing the clinical relevance of gut microbiome alterations in this population. In particular, prior studies have shown that distinct gut microbial compositions are associated with increased mortality risk among hemodialysis patients and may help identify individuals with a poorer prognosis. Highlighting this prognostic relevance would better justify the importance and clinical implications of the present study. 4. Page 14, Line 122: The matching procedure is unclear. The authors state that 96 hemodialysis patients were paired with 96 family members living with them. It is not clear what is meant by this statement or how the pairing was performed. The authors should clarify what they mean and explain their matching strategy. 5. Page 14, Lines 128-130: The authors state that patients and controls had “identical diet and living conditions,” but it is unclear how this was achieved. Even among cohabitating individuals, dietary variability can exist. The authors should elaborate on how diet and living conditions were assessed and controlled, and clarify the basis for this statement. 6. Page 14, Line 134: The manuscript states that Ethics Committee approval was obtained, but important details are missing. The authors should provide the approval number, specify the type of consent obtained from participants, and indicate whether any waiver of consent was granted, particularly given the retrospective nature of the study. Reviewer #4: What is novel in your multi-omics integration compared with previous studies? Does the paired design under identical dietary and living conditions represent the main innovation? Are these fecal or systemic markers? How feasible is their use in routine HD practice? Was diet standardized or monitored? For how long prior to sampling? Add a correlation network figure showing microbiome–metabolome interactions. Include a heatmap of significantly altered metabolites. Discuss potential interventions: Probiotics? Vitamin supplementation? Dietary modulation? Clearly define study limitations: Cross-sectional design; 16S rather than shotgun sequencing; Lack of serum metabolomics; Single-center cohort ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Ganesh Praneeth Roy Avula Reviewer #2: Yes: Shadrack Barffour Awuah Reviewer #3: No Reviewer #4: Yes: ahmed alshewered ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 10 May 2026 Dear Editor and Reviewers: A pleasant day to you! We sincerely thank you for the opportunity to revise our manuscript and for the constructive comments provided by the reviewers. We have carefully addressed all major concerns raised by Reviewers 2, 3, and 4. For initially unclear points, we consulted academic advisors and field professionals to ensure accurate understanding and proper responses. We believe the revised manuscript now meets the standards for publication in PLOS ONE. We have formatted the revised manuscript according to the PLOS ONE templates, including proper file naming, line numbering, title page, and figure formatting. We have corrected the funding information in the online submission system. The grant number is now consistent: No. ZF2024069. We have regenerated and uploaded high-resolution versions of all requested figures. Clarity has been substantially improved. We have addressed all editorial requirements as follows: no custom code was generated (SPSS/GraphPad Prism used); the funding statement has been amended to include “There was no additional external funding received for this study”; the funders had no role in the study; and all data underlying the findings are fully available within the manuscript and its Supporting Information files. Raw sequencing data were uploaded to a public database to meet transparency requirements. DOI: 10.57760/sciencedb.34128. These updates have been detailed in our revised cover letter. Below we provide a point-by-point response to each reviewer comment. All changes in the revised manuscript have been highlighted for your convenience. Thank you once again for your time and valuable input. We look forward to your response. Sincerely, Yours, Hailing Di Submitted filename: Response_Letter.docx 26 Jul 2026 Integrated Multi-Omics Reveals Dysbiosis in Hemodialysis Patients: A Multi-Center Study PONE-D-25-56310R1 Dear Dr. Di, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ze Xiang Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #3: Yes ********** Reviewer #3: (No Response) ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #3: No ********** PONE-D-25-56310R1 PLOS One Dear Dr. Di, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Ze Xiang Academic Editor PLOS One